huANGPTL3 Mouse
製品名
huANGPTL3 Mouse
製品ID
C001400
系統名
C57BL/6JCya-Angptl3tm1(hANGPTL3)/Cya
背景情報
C57BL/6JCya
状況
このマウス系統を論文で使用する場合は、「huANGPTL3 Mouse（カタログ番号C001400）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
ANL3, ANG-5, FHBL2, ANGPT5
NCBI ID
染色体
Chr 1
MGI ID
さらに
系統詳細
Angiopoietin-like 3 encoded by the ANGPTL3 gene is a member of the angiopoietin-like secretory growth factor family. The protein is mainly expressed in the liver and is a secreted glycoprotein related to angiopoietin structure. Mature human ANGPTL3 protein contains an N-terminal coiled-coil domain and a C-terminal fibrinogen (FBN)-like domain. The protein induces endothelial cell adhesion and migration by binding the FBN-like domain to integrin α5β3 and plays a role in regulating angiogenesis [1]. ANGPTL3 can directly inhibit lipoprotein lipase (LPL) and endothelial lipase (EL) which are closely related to the hydrolysis of circulating triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C). It can increase the level of circulating TG without changing the secretion or uptake of very low-density lipoprotein (VLDL) or HDL [2]. ANGPTL3 is a key determinant of HDL levels and is positively correlated with high-density lipoprotein cholesterol (HDL-C) in plasma. Loss-of-function mutations in the ANGPTL3 gene can lead to familial combined hyperlipidemia (FCH) [3]. In addition, ANGPTL3 plays a crucial role in biological or pathological processes related to lipid metabolism, angiogenesis, and hematopoiesis, such as atherosclerosis, carcinogenesis, nephrotic syndrome, diabetes, and liver disease [4].
This strain is a mouse Angptl3 gene humanized model. The mouse Angptl3 gene is replaced with the human ANGPTL3 gene sequence by gene editing technology, which expresses the human ANGPTL3 protein while retaining the signal peptide of mouse Angptl3. This model can be used to study the pathogenesis of metabolic diseases such as atherosclerosis, diabetes, and familial combined hyperlipidemia (FCH), as well as the development and screening of ANGPTL3-targeted drugs. The homozygous huANGPTL3 mice are viable and fertile.
参考文献
Conklin D, Gilbertson D, Taft DW, Maurer MF, Whitmore TE, Smith DL, Walker KM, Chen LH, Wattler S, Nehls M, Lewis KB. Identification of a mammalian angiopoietin-related protein expressed specifically in liver. Genomics. 1999 Dec 15;62(3):477-82.
Akoumianakis I, Zvintzou E, Kypreos K, Filippatos TD. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.
Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010 Dec 2;363(23):2220-7.
Mohamed F, Mansfield BS, Raal FJ. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. Curr Atheroscler Rep. 2022 Dec;24(12):959-967.
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12;391(10):913-925.
系統作製戦略
The mouse endogenous region from p.S17 to downstream of Exon 7 was replaced with the human ANGPTL3 region from p.S17 to downstream of Exon 7. The murine signal peptide was remained.
Figure 1. The gene editing strategy for generating huANGPTL3 mice.
適用分野
Metabolic diseases such as atherosclerosis and hyperlipidemia;
Angiogenesis and endothelial cell adhesion;
Development and screening of ANGPTL3-targeted drugs.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。